Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma

NCT04921995 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Nasopharyngeal Carcinoma
Unresectable Nasopharyngeal Carcinoma
Chemotherapy Effect
Immunotherapy
Stereotactic Body Radiation Therapy (SBRT)

Interventions

DRUG: Tislelizumab

Sponsor

Fudan University